In a study of NSCLC patients with acquired resistance to anti-PD-(L)1 therapy, Ricciuti et al. analyzed matched pre- and post-ICI tumor biopsies and identified recurrent genomic alterations—including mutations in STK11, B2M, JAK1/2, KEAP1, and MTOR—emerging only after immunotherapy exposure. The gene discussed is STK11; the disease is neoplasm.